Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | Director | May 19, 2022 | May 23, 2022 |
| Azenta, Inc.AZTA · Entity 4724 | Director | February 12, 2024 | February 13, 2024 |
| Merck & Co., Inc.MRK · Entity 2807 | Exec V-P & Chief Med Officer | May 10, 2016 | May 12, 2016 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | Director | May 12, 2022 | May 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date May 19, 2022 · Filed May 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2032-05-18 | Direct | 40,000 |
Reported balance
After 2022-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-19 · Grant · Acquired 40,000 · Balance 40,000 F1: This option shall vest and become exercisable in twelve equal quarterly installments following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in twelve equal quarterly installments following the grant date.
Azenta, Inc.
Report date February 12, 2024 · Filed February 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 13,042 |
Reported balance
After 2024-02-12 transaction · row 1
1 source rowRow 1 · 2024-02-12 · Grant · Acquired 2,465 · Balance 13,042 F1: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares.
Merck & Co., Inc.
Report date May 10, 2016 · Filed May 12, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.68 · Expires 2026-05-09 | Direct | 50,934 |
Reported balance
After 2016-05-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-05-10 · Grant · Acquired 50,934 · Balance 50,934 F2: The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. |
| Common StockSEC Table I · non-derivative | Direct | 41,473.147 |
Reported balance
Holding disclosure · report date 2016-05-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 41,473.147 F1: Holdings include shares acquired in dividend reinvestment transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include shares acquired in dividend reinvestment transactions.
F2: The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.
Rubius Therapeutics, Inc.
Report date May 12, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2032-05-11 | Direct | 25,000 |
Reported balance
After 2022-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-12 · Grant · Acquired 25,000 · Balance 25,000 F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2024 Filed Feb 13, 2024 21:10 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantCommon | 2,465 | $65.93 | $162,517.45 |
DisclosureSEC source: 0000950170-24-014560 · ownership.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,042 F1 · shares: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:21 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantCommon Stock | 3,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009728 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,577 F1 · price: Grant of unrestricted shares under the company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| May 19, 2022 Filed May 23, 2022 16:53 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001104659-22-063902 · tm2216627-5_4seq1.xml · derivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-05-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in twelve equal quarterly installments following the grant date. Read SEC document |
| May 12, 2022 Filed May 13, 2022 16:28 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001179110-22-003006 · edgar.xml · derivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-05-11 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| February 11, 2022 Filed Jun 9, 2022 21:07 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantCommon Stock | 1,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035452 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,973 F1 · price: Grant of unrestricted shares under the company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 21:12 UTC | Azenta, Inc. BRKS · Entity 4724 | SaleCommon Stock | 2,831 | $114.13 | $323,102.03 |
DisclosureSEC source: 0001209191-21-064446 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,051 Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:18 UTC | Azenta, Inc. BRKS · Entity 4724 | SaleCommon Stock | 1,760 | $90.00 | $158,400.00 |
DisclosureSEC source: 0001209191-21-032704 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,882 F1 · price: This represents the weighted average price for shares sold on May 13, 2021 at a range between $90.00 and $90.03 the reporting person will provide to the Securities and Exchange Commission, the issuer and any stockholder, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:35 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $23.25 | $0.00 |
DisclosureSEC source: 0001179110-21-005314 · edgar.xml · derivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-05-11 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 21:16 UTC | Azenta, Inc. BRKS · Entity 4724 | GrantCommon Stock | 1,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008464 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,642 F1 · price: Grant of unrestricted shares under the company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| May 21, 2020 Filed May 26, 2020 19:25 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001179110-20-006605 · edgar.xml · derivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 22:09 UTC | Azenta, Inc. BRKS · Entity 4724 | GrantCommon Stock | 2,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009326 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,882 F1 · price: Grant of unrestricted shares under the company's 2015 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| May 23, 2019 Filed May 28, 2019 19:59 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $16.27 | $0.00 |
DisclosureSEC source: 0001104659-19-032121 · a4.xml · derivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-22 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:29 UTC | Azenta, Inc. BRKS · Entity 4724 | GrantCommon Stock | 4,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008936 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,051 F1 · price: Grant of unrestricted shares under the company's 2015 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 21:00 UTC | Azenta, Inc. BRKS · Entity 4724 | GrantCommon Stock | 1,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-050509 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018 F1 · price: Grant of restricted shares under the company's 2015 Equity Incentive Plan. All shares vest on the date one day before the Company's 2019 Annual Meeting of Stockholders. Read SEC document |
| July 17, 2018 Filed Jul 18, 2018 16:33 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $23.00 | $0.00 |
DisclosureSEC source: 0001104659-18-045775 · a4.xml · derivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-07-16 F1 · derivative.exercise_date: This option shall vest in equal quarterly installments during the twelve quarters following the grant date. Read SEC document |
| May 10, 2016 Filed May 12, 2016 15:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 50,934 | $0.00 Strike: $54.68 | $0.00 |
DisclosureSEC source: 0001225208-16-033212 · doc4.xml · derivative · entry 2 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,934 Underlying: Common Stock · 50,934 shares Expires 2026-05-09 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| February 22, 2016 Filed Feb 24, 2016 17:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 7,738 | $50.77 | $392,858.26 |
DisclosureSEC source: 0001225208-16-027764 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,133.076 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance share units granted on 03/29/2013. Performance shares were paid out at 105 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 3,818 | $59.86 | $228,545.48 |
DisclosureSEC source: 0001225208-15-011278 · doc4.xml · derivative · entry 4 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,818 shares Expires 2015-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,980 | $59.86 | $118,522.80 |
DisclosureSEC source: 0001225208-15-011278 · doc4.xml · nonDerivative · entry 2 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,553.64 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-15-011278 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,533.64 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 46,440 | $0.00 Strike: $59.86 | $0.00 |
DisclosureSEC source: 0001225208-15-011278 · doc4.xml · derivative · entry 3 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,440 Underlying: Common Stock · 46,440 shares Expires 2025-04-30 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| February 23, 2015 Filed Feb 25, 2015 16:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 5,001 | $58.30 | $291,558.30 |
DisclosureSEC source: 0001225208-15-005608 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,477.447 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/30/2012. Performance shares were paid out at 102 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 41,265 | $0.00 Strike: $58.22 | $0.00 |
DisclosureSEC source: 0001225208-14-012825 · doc4.xml · derivative · entry 2 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,265 Underlying: Common Stock · 41,265 shares Expires 2024-05-08 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 9, 2015. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 4,103 | $58.22 | $238,876.66 |
DisclosureSEC source: 0001225208-14-012271 · doc4.xml · derivative · entry 3 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,103 shares Expires 2014-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,799 | $58.22 | $104,737.78 |
DisclosureSEC source: 0001225208-14-012271 · doc4.xml · nonDerivative · entry 2 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,920.788 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 4,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-012271 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,719.788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2014 Filed Feb 26, 2014 19:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 4,907 | $56.18 | $275,675.26 |
DisclosureSEC source: 0001225208-14-006333 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,438.832 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/31/2011. Performance shares were paid out at 86 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 4,479 | $44.98 | $201,465.42 |
DisclosureSEC source: 0001225208-13-011733 · doc4.xml · derivative · entry 4 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,479 shares Expires 2013-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 2,323 | $44.98 | $104,488.54 |
DisclosureSEC source: 0001225208-13-011733 · doc4.xml · nonDerivative · entry 2 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,072.034 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 4,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-011733 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,395.034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 48,309 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-13-011733 · doc4.xml · derivative · entry 3 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,309 Underlying: Common Stock · 48,309 shares Expires 2023-05-05 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 6, 2014. Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 22:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 5,392 | $42.52 | $229,267.84 |
DisclosureSEC source: 0001225208-13-005768 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,776 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/2010. Performance shares were paid out at 107 percent of target awards. Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 15,000 | $41.42 | $621,300.00 |
DisclosureSEC source: 0001225208-13-004734 · doc4.xml · derivative · entry 3 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2013-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 5,616 | $41.42 | $232,614.72 |
DisclosureSEC source: 0001225208-13-004734 · doc4.xml · nonDerivative · entry 2 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,384 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-004734 · doc4.xml · nonDerivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 54,845 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-12-011189 · doc4.xml · derivative · entry 2 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,845 Underlying: Common Stock · 54,845 shares Expires 2022-05-01 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 2, 2013. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 3,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-011189 · doc4.xml · derivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,818 Underlying: Common Stock · 3,818 shares Expires 2015-05-02 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 04, 2011 Filed May 6, 2011 14:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 55,970 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-11-013370 · doc4.xml · derivative · entry 2 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,970 Underlying: Common Stock · 55,970 shares Expires 2021-05-03 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 4, 2012. Read SEC document |
| May 04, 2011 Filed May 6, 2011 14:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 4,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-013370 · doc4.xml · derivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,103 Underlying: Common Stock · 4,103 shares Expires 2014-05-04 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 07, 2010 Filed May 11, 2010 20:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 36,014 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-10-012619 · doc4.xml · derivative · entry 2 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,014 Underlying: Common Stock · 36,014 shares Expires 2020-05-06 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 7, 2011. Read SEC document |
| May 07, 2010 Filed May 11, 2010 20:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 4,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-012619 · doc4.xml · derivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,479 Underlying: Common Stock · 4,479 shares Expires 2013-05-07 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| February 19, 2010 Filed Feb 22, 2010 22:25 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $37.49 | $0.00 |
DisclosureSEC source: 0001225208-10-005226 · doc4.xml · derivative · entry 2 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2020-02-18 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning February 19, 2011. Read SEC document |
| February 19, 2010 Filed Feb 22, 2010 22:25 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-005226 · doc4.xml · derivative · entry 1 Rosenblatt Michael · CIK 0001478797 · Exec V-P & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2013-02-19 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.